Innovation in migraine care is accelerating, with several developments likely to influence practice over the coming years.
One area to watch is next-generation CGRP pathway modulation. Beyond efficacy, researchers are examining durability of response, switching strategies, approaches to combination therapy, sometimes called layering, and predictors of non-response. There is emphasis on optimising outcomes in addition to expanding access.
Another important development is the expanding role of gepants. Their dual utility in acute and preventive treatment offers flexibility, and emerging comparative data may help clarify where they sit alongside established preventives. For clinicians managing complex patients, this versatility is particularly valuable.
Finally, advances in neuromodulation deserve close attention. Improvements in device usability, patient selection criteria, and mechanistic understanding are strengthening the evidence base. As reimbursement pathways evolve globally, accessibility may improve.
Taken together, these therapies signal a broader shift: migraine care is becoming more nuanced, mechanism-informed, and patient-centred. Staying abreast of these changes allows clinicians and researchers to refine treatment pathways and contribute meaningfully to the next phase of progress in headache medicine.
To register for the conference or submit an abstract, please use the links provided below.